Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, today announced the company has entered into a licensing agreement with the Pakistan pharmaceutical company Searle Co Ltd., for MAILISHU and 9MW0321, it’s Denosumab biosimilars, under which Searle will manufacture, register, and market the drugs in Pakistan.

Mabwell’s MAILISHU has been approved by the China National Medical Products Administration (NMPA) in March 2023, and 9MW0321 has been filed for MA approval. 

Dr. Datao Liu, Co-founder, Chairman of the Board, and CEO of Mabwell, said: “Mabwell is pleased to partner with Searle Co Ltd to commercialize and localize Denosumab biosimilars in Pakistan, an important country in China's Belt and Road Initiative with large market and great demand. This partnership will benefit the patients in Pakistan by providing high quality affordable biological medicines.” 

Dr. Syed Nadeem Ahmed, Group Managing Director & CEO of Searle Company Limited., said: “Partnership with Mabwell is an integral part of our strategy to develop further our biotechnology business in Pakistan. The goal of this project is not only to bring Mabwell products to Pakistan, but also to establish cooperation with such an innovative company as Mabwell. This cooperation also represents an important milestone for Searle Co Ltd., and for our patients in Pakistan that will ensure the social benefit from an increased access to high-quality affordable medicines”.

About Searle Co Ltd.,

The Searle Company Limited (TSCL) was established in Pakistan as a Private Limited Company on October 5, 1965 as a subsidiary of G.D. Searle & Co., USA.TSCL has been in pharmaceutical business for the past 48 years and is one of the top pharmaceutical companies in Pakistan having Eight state-of-the art manufacturing facilities and global presence in 18 countries. Today, Searle is among the top three companies of Pakistan in terms of revenue, and the fastest in terms of growth, market cap, market-derived portfolios and global recognition. TSCL have approximately 4000 direct and indirect employees, including a dedicated sales force that visits doctors, pharmacists, retail outlets, hospitals, and wholesalers to promote the company's products. The Searle Co Ltd., has also became Pakistan’s first pharmaceutical company to get GMP approval for its manufacturing facility from the Ministry of Health, Sultanate of Oman, A member of the Gulf Cooperation Council (GCC), the company’s filing on PSX showed. The approval will allow the company to further enhance its global footprint and raise the bar of the Pakistani pharmaceutical industry in the GCC region. The company is expanding rapidly in several regions of the world including South Asia, Southeast Asia, Africa, Francophone Africa, GCC, Commonwealth of Independent States (CIS), Canada, Europe, and Latin America (EU&LATAM), etc.